Avadel Pharmaceuticals Plans Financial Update Call
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company dedicated to transforming medicines for the betterment of lives, has announced an upcoming conference call set for May 7. This call will be hosted at 8:00 a.m. ET and will focus on providing a corporate update along with a comprehensive review of the financial results for the first quarter ending March 31, 2025.
Details of the Conference Call
Participants eager to attend the conference call can access a live audio webcast through the investor relations section of the Avadel website. Subsequently, a replay will be available for 90 days post-event, allowing those who were unable to attend the live call to stay informed. It is suggested that participants register at least 10 minutes ahead of the scheduled start time to ensure a smooth experience.
What to Expect from the Financial Results
During the call, key executives from Avadel Pharmaceuticals will discuss the performance metrics from the first quarter and elaborate on their strategies for addressing patient needs through innovative medication solutions. The financial report is expected to highlight the progress and developments that have taken place, particularly as they relate to their flagship product, LUMRYZ™.
About LUMRYZ™
LUMRYZ™ represents a breakthrough in the treatment of narcolepsy, being the first and only once-at-bedtime oxybate approved by the U.S. Food & Drug Administration (FDA). This product is designed specifically for treating cataplexy or excessive daytime sleepiness (EDS) in patients aged 7 and older. Avadel's commitment to innovation aims to improve the lives of those living with narcolepsy and enhance their overall treatment experience.
Company Background and Commitment
Avadel Pharmaceuticals is steadfast in its mission to transform treatment for numerous medical conditions. Through its dedicated research and development operations, the company seeks to create medications that offer significant improvements over traditional therapies. The focus is not just on obtaining regulatory approvals but also on ensuring that the medications are truly transformative for patients.
Contact Information for Investors and Media
For investor relations inquiries, Austin Murtagh can be reached via email at Austin.Murtagh@precisionAQ.com or by phone at (212) 698-8687. Media inquiries can be directed to Lesley Stanley at lestanley@realchemistry.com or (609) 273-3162.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to provide a corporate update and discuss Avadel's financial results for Q1 2025.
When will the conference call take place?
The call is scheduled for May 7 at 8:00 a.m. ET.
How can one access the live webcast of the conference call?
The live audio webcast can be accessed through the investor relations section of Avadel's website.
What is Avadel Pharmaceuticals' key product?
Avadel's key product is LUMRYZ™, used for treating narcolepsy in patients aged 7 and older.
Who can I contact for more information?
You can reach out to Austin Murtagh for investor inquiries or Lesley Stanley for media inquiries using the provided email addresses.
